Every 8-K that Precigen Inc (PGEN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PGEN filings page.
Precigen, Inc. reported a historic second quarter 2026, with total revenues of $55.0 million driven largely by PAPZIMEOS sales of $53.1 million for recurrent respiratory papillomatosis. The company generated net income of $20.1 million, or $0.06 per basic share, versus a $26.6 million loss a year earlier.
For the first six months of 2026, revenues reached $78.2 million and net income was $12.1 million, compared with an $80.8 million loss in the prior-year period, largely reflecting commercial PAPZIMEOS sales. R&D expenses declined due to capitalization of PAPZIMEOS manufacturing costs, while SG&A increased with launch-related spending. As of June 30, 2026, balance sheet figures (amounts in thousands) included cash and cash equivalents of $16,329, short-term investments of $21,879, long-term debt of $93,880, and shareholders' equity of $43,576, and management expects existing cash and PAPZIMEOS cash flows to fund operations through cash flow break-even by the end of 2026.
Precigen, Inc. reported results of its 2026 Annual Meeting. Stockholders approved an amendment to the 2023 Omnibus Incentive Plan that increases the shares of common stock available for equity awards by 7 million, following prior approval by the Board, subject to stockholder approval.
Stockholders also elected nine directors for one-year terms, ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approved a non-binding advisory vote on executive compensation. Each management proposal received substantial support based on the reported vote totals.
Precigen, Inc. reported sharply improved results for the quarter ended March 31, 2026, driven by the US launch of PAPZIMEOS for recurrent respiratory papillomatosis. Total revenues were $23.3 million, up from $1.3 million a year earlier, with $21.6 million from PAPZIMEOS sales.
The company’s net loss narrowed to $7.9 million, or $0.02 per share, compared with a net loss of $54.2 million, or $0.18 per share, in the prior-year quarter. Management highlighted approximately 400 patients enrolled in the PAPZIMEOS hub and reiterated that current cash, investments and expected PAPZIMEOS cash collections are anticipated to fund operations through cash flow break-even by the end of 2026.
Precigen reported a pivotal 2025 as it shifted to a commercial-stage model following FDA approval and US launch of PAPZIMEOS for recurrent respiratory papillomatosis. Total revenues were $9.7 million for the year, up from $3.9 million in 2024, driven by $3.4 million of PAPZIMEOS product revenue and higher collaboration and licensing revenue of $1.8 million.
Research and development expenses fell to $41.3 million, a $11.7 million decrease tied to pipeline prioritization and the ActoBio shutdown, while selling, general and administrative costs rose to $70.1 million as the company invested in PAPZIMEOS commercial readiness and launch. Operating loss improved modestly to $110.5 million.
Other non-operating items dominated the bottom line. A $139.5 million increase in the fair value of warrant liabilities and a $179.0 million non-cash deemed dividend on preferred stock led to a net loss attributable to common shareholders of $429.6 million, or $1.37 per share, compared with $126.2 million, or $0.47 per share, in 2024. As of December 31, 2025, cash and cash equivalents were $30.2 million and short-term investments were $67.6 million. Management expects the current cash position and PAPZIMEOS sales to fund operations through cash flow break-even by the end of 2026.
Precigen, Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended September 30, 2025. The press release, dated November 13, 2025, is included as Exhibit 99.1 and relates to the company’s results of operations and financial condition for that quarter. The company notes that this information, including the exhibit, is being furnished rather than filed, which affects how it is treated under securities laws.
Precigen, Inc. reported that on September 15, 2025, holders of its 8.00% Series A Convertible Perpetual Preferred Stock converted 79,000 preferred shares, with an aggregate stated value of $79,000,000, into 54,937,411 shares of common stock. The common shares were delivered on September 17, 2025 under the existing conversion terms, using a rate of 695.4103 common shares per $1,000 of stated value.
The exchange was conducted with existing security holders and relied on the exemption from registration in Section 3(a)(9) of the Securities Act of 1933, with no commission or other remuneration paid for soliciting the exchange.
Precigen, Inc. has entered into a new senior secured term loan agreement providing up to $125 million in non-dilutive financing with investment entities managed by Pharmakon Advisors. The facility includes an initial $100 million tranche funded on the closing date and a delayed draw tranche of $25 million available, subject to conditions, until June 29, 2027, with all term loans maturing on September 3, 2030. The debt bears interest at three‑month Term SOFR, subject to a 3.75% floor, plus 6.50%, with principal repaid in eight equal quarterly installments beginning September 29, 2028. The loans are secured by substantially all of Precigen’s U.S. assets, including intellectual property, and are subject to customary covenants and events of default, as well as minimum net sales and minimum liquidity requirements. Precigen plans to use the proceeds for general corporate and working capital purposes.
Precigen, Inc. entered into a Commercial Supply Agreement with Catalent Maryland, Inc. for the commercial manufacture of PAPIZEMOS. Under the agreement, Catalent will provide services such as analytical work, development, processing, validation and product maintenance as defined in a Plan Document.
During the term of the agreement, Precigen has agreed to use Catalent exclusively for external commercial fill-and-finish manufacturing of all reported PAPIZEMOS volumes in the defined territory. If the Plan Document sets any minimum annual batch requirements, Precigen must purchase at least those amounts in the relevant contract years. Precigen will pay Catalent agreed prices and fees for these services, which are subject to annual adjustments for factors including labor, utilities and overhead, and will also pay certain maintenance fees and expenses.
The initial term runs for three years from the effective date and then renews automatically in one-year increments unless either party gives at least twelve months’ written notice before the end of the current term. The agreement may be terminated by either party for material breach or certain other specified circumstances after any applicable cure period and includes customary provisions on quality, delivery, warranties, intellectual property, confidentiality and indemnification.
Precigen, Inc. filed a current report to note that it provided a slide presentation at a webcast investor conference held on August 18, 2025 at 8:00 a.m. Eastern Time. The presentation is included as Exhibit 99.1 to the report but is furnished rather than filed for securities law purposes.